Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Arkansas Children's Hospital
mi
from
Little Rock, AR
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Sharp Mary Birch Hospital for Women and Newborns
mi
from
San Diego, CA
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Sharp Mary Birch Hospital for Women and Newborns
mi
from
San Diego, CA
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Christiana Care Health System
mi
from
Newark, DE
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Christiana Care Health System
mi
from
Newark, DE
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
University of Miami
mi
from
Miami, FL
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Riley Hospital for Children at IU Health
mi
from
Indianapolis, IN
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Riley Hospital for Children at IU Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
University of Louisville
mi
from
Louisville, KY
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Mid Atlantic Neonatology Associates
mi
from
Morristown, NJ
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Mid Atlantic Neonatology Associates
mi
from
Morristown, NJ
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Providence St. Vincent Medical Center
mi
from
Portland, OR
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Providence St. Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Study to Assess the Tolerability of a Single Dose of AF-219 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Study to Assess the Tolerability of a Single Dose of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated:  11/19/2015
American Health Research Inc.
mi
from
Charlotte, NC
A Study to Assess the Tolerability of a Single Dose of AF-219 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Study to Assess the Tolerability of a Single Dose of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated: 11/19/2015
American Health Research Inc.
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Trial to Evaluate a Device for the Treatment of OSA and Snoring
A Multi Center, Open Label Study to Evaluate a Tongue Advancement Retainer Device in the Treatment of Subjects With Obstructive Sleep Apnea and Snoring (OPEN Trial)
Status: Enrolling
Updated:  11/22/2015
Senta Clinic
mi
from
San Diego, CA
A Trial to Evaluate a Device for the Treatment of OSA and Snoring
A Multi Center, Open Label Study to Evaluate a Tongue Advancement Retainer Device in the Treatment of Subjects With Obstructive Sleep Apnea and Snoring (OPEN Trial)
Status: Enrolling
Updated: 11/22/2015
Senta Clinic
mi
from
San Diego, CA
Click here to add this to my saved trials
A Trial to Evaluate a Device for the Treatment of OSA and Snoring
A Multi Center, Open Label Study to Evaluate a Tongue Advancement Retainer Device in the Treatment of Subjects With Obstructive Sleep Apnea and Snoring (OPEN Trial)
Status: Enrolling
Updated:  11/22/2015
Visalia Medical Clinic
mi
from
Visalia, CA
A Trial to Evaluate a Device for the Treatment of OSA and Snoring
A Multi Center, Open Label Study to Evaluate a Tongue Advancement Retainer Device in the Treatment of Subjects With Obstructive Sleep Apnea and Snoring (OPEN Trial)
Status: Enrolling
Updated: 11/22/2015
Visalia Medical Clinic
mi
from
Visalia, CA
Click here to add this to my saved trials
A Trial to Evaluate a Device for the Treatment of OSA and Snoring
A Multi Center, Open Label Study to Evaluate a Tongue Advancement Retainer Device in the Treatment of Subjects With Obstructive Sleep Apnea and Snoring (OPEN Trial)
Status: Enrolling
Updated:  11/22/2015
Royal North Shore Hospital
mi
from
St. Leonards,
A Trial to Evaluate a Device for the Treatment of OSA and Snoring
A Multi Center, Open Label Study to Evaluate a Tongue Advancement Retainer Device in the Treatment of Subjects With Obstructive Sleep Apnea and Snoring (OPEN Trial)
Status: Enrolling
Updated: 11/22/2015
Royal North Shore Hospital
mi
from
St. Leonards,
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Birmingham, AL
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Phoenix, AZ
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Miami, FL
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Tampa, FL
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Chicago, IL
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Wichita, KA
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
New Orleans, LA
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Minneapolis, MN
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Cincinnati, OH
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Charleston, SC
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Spartanburg, SC
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Spartanburg, SC
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Nashville, TN
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
Clinical Research Facility
mi
from
Colchester, VT
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
Clinical Research Facility
mi
from
Colchester, VT
Click here to add this to my saved trials
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/24/2015
mi
from
Leuven,
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/24/2015
mi
from
Leuven,
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Stanford University
mi
from
Stanford, CA
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Ohio State University
mi
from
Columbus, OH
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Vanderbilt University
mi
from
Nashville, TN
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Fred Hutchinson Cancer Research Center - Seattle Cancer Care Alliance
mi
from
Seattle, WA
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Fred Hutchinson Cancer Research Center - Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Washington University, St. Louis
mi
from
St. Louis, MO
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Washington University, St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Weill-Cornell Medical College
mi
from
New York, NY
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis
Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  11/25/2015
University of Colorado Denver
mi
from
Aurora, CO
Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis
Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 11/25/2015
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis
Status: Enrolling
Updated:  11/26/2015
Clinical Research Facility
mi
from
Los Angeles, CA
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis
Status: Enrolling
Updated: 11/26/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis
Status: Enrolling
Updated:  11/26/2015
Clinical Research Facility
mi
from
Denver, CO
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis
Status: Enrolling
Updated: 11/26/2015
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials